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1. INTRODUCTION {#jso25643-sec-0050}
===============

Radical prostatectomy (RP) is a common surgical procedure used worldwide as curative treatment for prostate cancer (Pca). However, there is a substantial risk of erectile dysfunction and urinary incontinence postoperatively.[1](#jso25643-bib-0001){ref-type="ref"}, [2](#jso25643-bib-0002){ref-type="ref"}, [3](#jso25643-bib-0003){ref-type="ref"} High surgical volume has been associated with better outcomes including better cancer control and less postoperative erectile dysfunction and urinary incontinence. Furthermore, there is a large variation between individual surgeons, also among those who perform a large number of RP\'s.[4](#jso25643-bib-0004){ref-type="ref"}, [5](#jso25643-bib-0005){ref-type="ref"} Therefore, there is a need for a uniform registration of data on pre‐, peri, and post‐operative variables after RP including case mix as a basis for quality assurance and benchmarking of individual surgeons and hospitals.

In 2015, a form for prostatectomies in Sweden (PiS) was implemented in the National Prostate Cancer Register of Sweden.[6](#jso25643-bib-0006){ref-type="ref"} The aim of this form is to collect comprehensive data for men with Pca who undergo RP to support quality assurance and quality improvement. There are no legal obligations for a department to perform this registration. For research purposes, there is also a need for more data on the cases such as, for example, socioeconomic status, comorbidity to assess case mix but to minimize the data collection in PiS, these data are captured by cross linkages to other nationwide population‐based health care registries and demographic databases. Here, we report the preliminary results obtained in PiS.

2. MATERIALS AND METHODS {#jso25643-sec-0060}
========================

2.1. The National Prostate Cancer Register (NPCR) of Sweden {#jso25643-sec-0070}
-----------------------------------------------------------

The National Prostate Cancer Register of Sweden captures comprehensive data for 98% of all incident cases of Pca in Sweden with the aim to assess health care for men with Pca.[6](#jso25643-bib-0006){ref-type="ref"}

Data in NPCR are collected by the use of four forms: a diagnostic form with information on diagnostic characteristics, primary treatment and work‐up form with information on subsequent work‐up and medical treatment and two separate treatment forms for curatively intended procedures, one for radiotherapy and one for prostatectomy (PiS). The aim of this paper was to describe the content of the PiS form.

2.2. PiS form {#jso25643-sec-0080}
-------------

Two versions of a PiS form has been in use since January 2015, a shorter version with 60 variables and an extensive version with 83 variables. The version that is used is determined by each reporting department.

Table [1](#jso25643-tbl-0001){ref-type="table"} reports the complete list of variables and the capture for each variable which was defined as the percentage of nonmissing values out of the total number of cases recorded for each variable for the short and extensive form respectively, in 2016.

###### 

Capture of variables in the prostatectomy in Sweden (PiS) form in the National Prostate Cancer Register (NPCR)

  -----------------------------------
  ![](JSO-120-803-g005.jpg "image")
  ![](JSO-120-803-g006.jpg "image")
  -----------------------------------

John Wiley & Sons, Ltd.

Overall, out of 3096 procedures registered, 833 (27%) were recorded by use of the short form and 2263 (73%) with the extensive form.

The collected variables include information regarding the preoperative characteristics, for example, data on the histopathological characteristics in the core biopsies, data on TNM classification, results from imaging, perioperative data, for example, type of RP, operative time, perioperative blood loss, hospital and surgeon code, and postoperative data, for example, histopathological assessment of surgical specimen, prescribed drug therapy after surgery etc.

A full variable list for the two PiS forms is available in Swedish at: <https://www.cancercentrum.se/globalassets/cancerdiagnoser/prostatacancer/dokument/radikalop_manual_2018.pdf>

Specifically, 70/83 (84%) variables had ≥95% of completeness, 5/83 (6%) had a completeness between 90% and 95%, 2/83 (2%) had a total completeness between 80% and 90% and 6/83 (7%) had a completeness below 80%. Specification regarding the inclusion criteria for some specific variable is reported in Table S1.

These data are subsequently reported online at the secured Information Network for Cancer Care (INCA) platform within 24 hours to the reporting unit with comparisons between surgeons at the department, and the average for the health care region as well as for the entire nation (Figure [1](#jso25643-fig-0001){ref-type="fig"}).[7](#jso25643-bib-0007){ref-type="ref"} In addition, the number of RP\'s performed per year at each hospital and the number of RP\'s per surgeon is publicly reported at [www.npcr.se/RATTEN](http://www.npcr.se/RATTEN) in April for the preceding year.[8](#jso25643-bib-0008){ref-type="ref"}

![Display of proportion of positive margin per surgeon at a department, the mean for all surgeons at the hospital, and the mean for all surgeons in the nation. Data for a department are displayed 24 hours after reporting at the secured server Information Network for Cancer Care for this department, several other variables besides positive margins including operating time and preoperative blood loss are also reported in a similar fashion. The demonstrated data are fictitious \[Color figure can be viewed at wileyonlinelibrary.com\]](JSO-120-803-g001){#jso25643-fig-0001}

NPCR has been linked with other national healthcare registries and demographic databases to obtain information on comorbidities, socioeconomic factors, and outcome in Prostate Cancer data Base Sweden (PCBaSe).[9](#jso25643-bib-0009){ref-type="ref"}, [10](#jso25643-bib-0010){ref-type="ref"}

The Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA)[11](#jso25643-bib-0011){ref-type="ref"} holds information regarding educational level, income, civil status, and type of employment.

The National Patient Registry[12](#jso25643-bib-0012){ref-type="ref"} holds information regarding all in‐patient care in Sweden from 1987 including surgical procedures and dates of admission and discharge. The Charlson comorbidity index (CCI) was calculated by the use of discharge diagnoses in this registry based on data up to 10 years before the date of the RP, as previously described.[9](#jso25643-bib-0009){ref-type="ref"}

3. RESULTS {#jso25643-sec-0090}
==========

Out of all 3881 RP\'s performed and registered in Sweden in 2016, 3096 (80%) RP\'s had been registered with a PiS form, 2870 (92%) had also been reported to the National Patient Registry, while 226 (8%) had been reported with a PiS form only and 785 had been registered in the Patient Registry only (Figure [2](#jso25643-fig-0002){ref-type="fig"}). To assess the characteristics of men for whom RP was registered in one of the two registers or in both registers, we compared data in NCR (except for the data retrieved in PiS) for men who were registered with a PiS form with those who had their RP registered only the Patient Registry (Table S2).

![Number of radical prostatectomies registered in The Patient Registry only, Patient Registry and in the prostatectomies in Sweden (PiS) form, and in PiS only in 2016 \[Color figure can be viewed at wileyonlinelibrary.com\]](JSO-120-803-g002){#jso25643-fig-0002}

Men reported with a PiS form only were more frequently operated in the metropolitan areas of Västra Götaland and Stockholm where a high proportion of RP\'s are performed in private clinics, and these men were younger and had more often undergone a robot‐assisted radical prostatectomy (RARP).

Overall, 2440 (79%) of the prostatectomies were performed as primary treatment and 570 (18%) after an initial period of active surveillance.

A total of 2605 (84%) RP\'s were performed as RARP and 491 (16%) were performed as retropubic radical prostatectomy (RRP) (Table [2](#jso25643-tbl-0002){ref-type="table"}). Median age at date of RP was 65 years (IQR 60‐69) for RARP and 67 years (IQR 62‐70) for RRP. Men who underwent RARP had a lower number of cores per diagnostic biopsy session compared with the RRP group (median number of biopsies: RARP 10 \[IQR 10‐12\]; RRP 12 \[IQR 10‐12\]; *P* \< .001). The number of biopsy procedures from the first diagnosis date to the radical prostatectomy date is not collected in PiS form. However, possible explanations for difference in the number of biopsy cores are that magnetic resonance imaging (MRI) guided biopsies were more commonly used in the first diagnostic set before RARP than before RRP (12% vs 7%). Despite the similar proportion of re‐biopsies before RP (RARP 16% vs RRP 13%), the use of biopsies guided by MRI was three times higher before RARP than before RRP (RARP 24% vs RRP 8%).

###### 

Preoperative characteristics of men who underwent radical prostatectomy in Sweden and registered in prostatectomy in Sweden (PiS) form in 2016

                                RARP               RRP
  ----------------------------- ------------------ ------------------
  No. procedures (%)            2605 (84.1)        491 (15.9)
  Age, y                                           
  Median (IQR)                  65.0 (60.0‐69.0)   67.0 (62.0‐70.0)
  PSA (ng/mL)                                      
  Median (IQR)                  6.6 (4.5‐10.0)     7.5 (5.2‐11.4)
  PSA                           No (%)             
  \<3 ng/mL                     99 (3.8)           6 (1.2)
  3 to 10 ng/mL                 1863 (71.5)        337 (68.6)
  10.1 to 20 ng/mL              462 (17.7)         97 (19.8)
  \>20 ng/mL                    175 (6.7)          48 (9.8)
  Missing                       6 (0.2)            3 (0.6)
  Prostate volume                                  
  Median (IQR)                  35 (28‐47)         38 (30.50)
  \<30 gr                       757 (29.1)         111 (22.6)
  30 to 60 gr                   1441 (55.3)        282 (57.4)
  60 to 90 gr                   251 (9.6)          55 (11.2)
  \>90 gr                       65 (2.5)           14 (2.9)
  Missing                       91 (3.5)           29 (5.9)
  Number of cores                                  
  Median (IQR)                  10 (10‐12)         12 (10‐12)
  ≤9                            232 (8.9)          48 (9.8)
  10 to 12                      2187 (84)          401 (81.7)
  ≥13                           146 (5.6)          33 (6.7)
  Missing                       40 (1.5)           9 (1.8)
  Number of positive cores                         
  Median (IQR)                  4 (2--6)           4 (2--6)
  ≤2                            832 (31.9)         136 (27.7)
  3 to 4                        783 (30.1)         136 (27.7)
  5 to 6                        543 (20.8)         105 (21.4)
  \>6                           402 (15.4)         103 (21.0)
  Missing                       45 (1.7)           11 (2.2)
  Total mm of cancer in cores                      
  Median (IQR)                  11.5 (4.8‐23.0)    13.2 (5.9‐31.0)
  cT Stage                                         
  T1a/T1b                       29 (1.1)           10 (2.0)
  T1c                           1647 (63.2)        289 (58.9)
  T2                            797 (30.6)         174 (35.4)
  T3                            89 (3.4)           14 (2.9)
  T4                            1 (0.0)            1 (0.2)
  Missing                       42 (1.6)           3 (0.6)
  cN Stage                                         
  N0                            1044 (40.1)        190 (38.7)
  N1                            41 (1.6)           10 (2.0)
  NX                            1520 (58.3)        291 (59.3)
  Missing                       0 (0.0)            0 (0.0)
  cM Stage                                         
  M0                            2546 (97.7)        484 (98.6)
  M1                            10 (0.4)           3 (0.6)
  MX                            49 (1.9)           4 (0.8)
  Missing                       40 (0.0)           0 (0.0)
  Gleason grade groups                             
  GGG1                          905 (34.7)         138 (28.1)
  GGG2                          1088 (41.8)        186 (37.9)
  GGG3                          341 (13.1)         94 (19.1)
  GGG4                          174 (6.7)          39 (7.9)
  GGG5                          82 (3.1)           32 (6.5)
  Missing                       15 (0.6)           2 (0.4)
  Risk category                                    
  Very low‐risk                 131 (5.0)          28 (5.7)
  Low‐risk                      552 (21.2)         64 (13.0)
  Intermediate‐risk             1388 (53.3)        278 (56.6)
  High‐risk                     320 (12.3)         84 (17.1)
  Locally advanced              79 (3.0)           9 (1.8)
  Regionally metastatic         62 (2.4)           16 (3.3)
  Distant metastasis            15 (0.6)           4 (0.8)
  Missing                       58 (2.2)           8 (1.6)
  Charlson Comorbidity Index                       
  0                             2246 (86.2)        398 (81.1)
  1                             249 (9.6)          56 (11.4)
  2                             76 (2.9)           30 (6.1)
  3+                            34 (1.3)           7 (1.4)
  Missing                       0 (0.0)            0 (0.0)
  Educational level                                
  Low                           519 (19.9)         141 (28.7)
  Intermediate                  1149 (44.1)        228 (46.4)
  High                          921 (35.4)         121 (24.6)
  Missing                       16 (0.6)           1 (0.2)
  Civil status                                     
  Unmarried                     807 (31.0)         179 (36.5)
  Married                       1795 (68.9)        312 (63.5)
  Missing                       3 (0.1)            0 (0.0)
  Income                                           
  Q1                            616 (23.6)         156 (31.8)
  Q2                            645 (24.8)         125 (25.5)
  Q3                            650 (25.0)         135 (27.5)
  Q4                            691 (26.5)         75 (15.3)
  Missing                       3 (0.1)            0 (0.0)

*Note*: Number of cores = number of cores in biopsy session in which Pca was diagnosed. The National Care Program recommends that 10 to 12 cores should be obtained in the first set of systematic biopsies; Educational level: low = compulsory school, \<10 years; intermediate = upper secondary school, 10--12 years; high = college or university, \>12 years; Quartile of income: Q1 lowest -- Q4 highest; Risk categories: very low‐risk (T1c, GGG1 \[GS 6\], Prostate‐specific antigen \[PSA\] \<10 ng/mL, PSA density \<0.15, number of cores positive for cancer ≤4, cancer extension at biopsy \<8 mm), low‐risk (T1‐2, PSA \<10 ng/mL and GGG1), intermediate‐risk (T1‐2, GGG2 or 3 \[GS 7\] and/or PSA 10 to \<20 ng/mL), high‐risk (T3 and/or GGG 4 or 5 GS 8‐10 and/or PSA 20 to 50 ng/mL), very high‐risk (T4, PSA 50 to 200 ng/mL, any N stage, M0), regionally metastatic (T4 and/or N1 and/or PSA 50 to 100 ng/mL in the absence of distant metastases \[M0 or Mx\]), and distant metastases (PSA above 100 ng/mL or M1).

Abbreviations: IQR, inter‐quartile range; PSA, prostate‐specific antigen; RARP, robot‐assisted radical prostatectomy; RRP, retropubic radical prostatectomy.

John Wiley & Sons, Ltd.

Irrespective of type of RP, the majority of men were diagnosed with an intermediate‐risk Pca (53% RARP vs 56% RRP) and had a CCI of zero.

Men who underwent RARP had a slightly longer operative time (median operating time: RARP 155 minutes \[IQR 124‐190\]; RRP 129 minutes \[IQR 105‐171\]; *P* \< .001) but smaller blood loss (median intraoperative blood loss: RARP 100 mL \[IQR 50--200\], RRP 700 mL \[IQR 500‐1100\]; *P* \< .001) (Table [3](#jso25643-tbl-0003){ref-type="table"}). Furthermore, men who underwent RARP more frequently received a nerve sparing procedure compared to men who underwent a RRP (RARP 79% vs RRP 50%), more frequently underwent a lymph node dissection (RARP 16% vs RRP 12%), more often had stage pT2 (RARP 61% vs RRP 55%) but less often had pT3 (RARP 8% vs RRP 15%) and were upstaged less often (RARP 27% vs RRP 35%).

###### 

Peri‐ and post‐operative performance data on radical prostatectomy in 2016

                            RARP            RRP
  ------------------------- --------------- -----------------
                            No (%)          
  Operation time, min                       
  Median (IQR)              155 (124‐190)   129.5 (105‐171)
  ≤120                      435 (16.7)      117 (23.8)
  120 to 150                453 (17.4)      62 (12.6)
  150 to 180                438 (16.8)      36 (7.3)
  \>180                     545 (20.9)      57 (11.6)
  Missing                   734 (28.2)      219 (44.6)
  Blood loss, mL                            
  Median (IQR)              100 (50‐200)    700 (500‐1100)
  \<100                     619 (23.8)      1 (0.2)
  100 to 249                951 (36.5)      11 (2.2)
  250 to 499                273 (10.5)      44 (9.0)
  500 to 999                75 (2.9)        120 (24.4)
  ≥1000                     12 (0.5)        93 (18.9)
  Missing                   675 (25.9)      222 (45.2)
  Lymph node dissection                     
  Not performed             2098 (80.5)     417 (84.9)
  Limited                   14 (0.5)        6 (1.2)
  Extended                  404 (15.5)      52 (10.6)
  Missing                   89 (3.4)        16 (3.3)
  Nerve sparing procedure                   
  Yes                       2062 (79.2)     246 (50.1)
  No                        539 (20.7)      220 (44.8)
  Missing                   4 (0.2)         25 (5.1)
  Surgical margin status                    
  Negative                  1731 (66.8)     324 (66.4)
  Positive                  790 (30.5)      134 (27.5)
  Missing                   70 (2.7)        30 (6.1)
  pT stage                                  
  pT0                       8 (0.3)         1 (0.2)
  pT2                       1586 (60.9)     271 (55.2)
  pT3a                      776 (29.8)      138 (28.1)
  pT3b                      216 (8.3)       73 (14.9)
  pT4                       8 (0.3)         2 (0.4)
  Missing                   11 (0.4)        6 (1.2)
  pN stage                                  
  N0                        399 (78.7)      53 (71.6)
  N1                        106 (20.9)      20 (27.0)
  Missing                   2 (0.4)         1 (1.4)
  Upgrading                                 
  No                        1596 (61.3)     321 (65.4)
  Yes                       987 (37.9)      166 (33.8)
  Missing                   22 (0.8)        4 (0.8)
  Upstaging                                 
  No                        1810 (69.5)     294 (61.9)
  Yes                       727 (27.9)      172 (35.2)
  Missing                   68 (2.6)        25 (2.9)

*Note*: Limited lymph node dissection (LND): LND performed at the level of the obturator fossa including the obturatory nerve area; Extended LND: extended to the presacral region; Upgrading: defined as a GGG (Gleason Grade Group) at pathological specimen of radical prostatectomy higher than the GGG in biopsies; Upstaging: tumor diagnosed as a T1a/b, T1c or T2 preoperatively that was found to be a pT3a, pT3b or pT4 at examination of RP specimen or a T3 tumor at diagnosis is found to be a pT4 or N0 preoperatively found that had N1 disease at examination of RP specimen.

Abbreviations: RARP, robot‐assisted radical prostatectomy; RRP, retropubic radical prostatectomy.
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Data were reported from 20 departments performing RARP and 14 departments performing RRP. At 17/20 departments (85%) where RARP was used, more than 50 procedures were performed whereas, for RRP, only one out of 14 departments performed more than 50 procedures (Figure [3](#jso25643-fig-0003){ref-type="fig"}). The Swedish national guidelines for prostate cancer care recommends that each RP surgeon should perform 25 or more RP\'s per year and that there should be at least two RP surgeons at each department.

![Number of radical prostatectomies recorded in prostatectomy in Sweden for each hospital in 2016. Area between vertical lines represents the number of RP\'s for each single surgeon. Red dashed line represents limit for low volume (50 RP\'s/year) as defined in the Swedish National Prostate Cancer Care programme (at least two surgeons that each perform 25 or more RP\'s). Departments where less than 5 RP\'s are not displayed. RP, radical prostatectomy \[Color figure can be viewed at wileyonlinelibrary.com\]](JSO-120-803-g003){#jso25643-fig-0003}

Overall, 76% of all RPs were performed by surgeons who performed more than 25 RP/year.

A total of 91 surgeons were registered performing RARP and 69 performing RRP; 47% of RARP surgeons performed more than 25 RP/year while only 10% of RRP surgeons performed 25 procedures or more.

There were large variations in the use of RP among the Swedish counties (Figure [4](#jso25643-fig-0004){ref-type="fig"}). The highest number of RARP per 100 000 men in Värmland county (297/100 000 men) and the highest number of RRP in Kalmar county (126/100 000 men).

![Age‐standardized incidence of prostatectomies per county in Sweden in 2016. No data were delivered from the county of Jämtland regarding RP performed in 2016 to NPCR. In the Jämtland county the incidence of RRP and RRP combined was 157/100.000 according to the Patient Registry. RP, Radical prostatectomy; RRP, retropubic radical prostatectomy \[Color figure can be viewed at wileyonlinelibrary.com\]](JSO-120-803-g004){#jso25643-fig-0004}

4. DISCUSSION {#jso25643-sec-0100}
=============

The introduction of a national registration of radical prostatectomy in a clinical cancer register shows that such a registration is feasible even without being mandated by law.

Limitations of our data collected by use of a specific form for prostatectomy in NPCR are that capture was not complete and compared to compulsory registration to the Patient Registry there was some selection of younger and healthier men in our registration as these men more often underwent RARP in private practise. However, a capture rate of 80% already in the second year of the registration and a high completeness data for each variable in the PiS form are strengths of our registration.

Other initiatives in the same area include the British Association of Urological Surgeons (BAUS) RP audit with a complete capture of all RP\'s performed in England with pre‐, peri and post‐operative data per surgeon (<https://www.baus.org.uk/_userfiles/pages/files/Publications/Audit/Radical_Prostatectomy_2016_final_analysis.pdf>).

We believe these registers will become useful tools for quality assurance and benchmarking. Rapid feedback to health care providers is necessary and public, transparent reporting is necessary to achieve the optimal impact of such data.[8](#jso25643-bib-0008){ref-type="ref"}

5. CONCLUSIONS {#jso25643-sec-0110}
==============

It is possible to collect detailed data on cancer characteristics, case mix, case load, surgical method, and technical aspects of the performance of radical prostatectomy in a nationwide, population‐based register. Rapidly and transparently reported, these data are useful tools for quality assurance.
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SYNOPSIS {#jso25643-sec-0160}
========

We report on a nationwide, population‐based register with transparent reporting of data on the performance of radical prostatectomy. These data are useful tools for quality assurance.
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